Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

P Lewis; P Marsden; T Gee; T Nunan; M Malsey; S Griffin; J Dussek

doi:10.1016/s0140-6736(94)90753-6

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

P Lewis, P Marsden, T Gee, T Nunan, M Malsey, S Griffin, J Dussek

PET Imaging Centre Facility

Research output: Contribution to journal › Article › peer-review

213 Citations (Scopus)

Abstract

Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.

Original language	English
Pages (from-to)	1265-1266
Number of pages	2
Journal	The Lancet
Volume	344
Issue number	8932
DOIs	https://doi.org/10.1016/s0140-6736(94)90753-6
Publication status	Published - 5 Nov 1994

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s0140-6736(94)90753-6

Cite this

@article{78f641aad4a2488eaaa57ac6020ecd3b,

title = "Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer",

abstract = "Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.",

author = "P Lewis and P Marsden and T Gee and T Nunan and M Malsey and S Griffin and J Dussek",

year = "1994",

month = nov,

day = "5",

doi = "10.1016/s0140-6736(94)90753-6",

language = "English",

volume = "344",

pages = "1265--1266",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8932",

}

TY - JOUR

T1 - Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

AU - Lewis, P

AU - Marsden, P

AU - Gee, T

AU - Nunan, T

AU - Malsey, M

AU - Griffin, S

AU - Dussek, J

PY - 1994/11/5

Y1 - 1994/11/5

N2 - Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.

AB - Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.

U2 - 10.1016/s0140-6736(94)90753-6

DO - 10.1016/s0140-6736(94)90753-6

M3 - Article

C2 - 7967988

SN - 0140-6736

VL - 344

SP - 1265

EP - 1266

JO - The Lancet

JF - The Lancet

IS - 8932

ER -

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this